Revance Therapeutics (NASDAQ:RVNC) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Revance Therapeutics (NASDAQ:RVNC) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.12, Briefing.com reports. The business had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. The business’s revenue for the quarter was up 20.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.80) EPS.

Revance Therapeutics Stock Up 19.7 %

Shares of NASDAQ:RVNC traded up $0.58 during trading on Friday, reaching $3.53. The stock had a trading volume of 5,105,533 shares, compared to its average volume of 1,912,250. Revance Therapeutics has a 52 week low of $2.30 and a 52 week high of $20.56. The firm has a market capitalization of $368.70 million, a price-to-earnings ratio of -0.97 and a beta of 0.98. The stock has a fifty day simple moving average of $3.11 and a two-hundred day simple moving average of $4.15.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on RVNC shares. HC Wainwright lowered their price objective on shares of Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Stifel Nicolaus decreased their target price on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday. The Goldman Sachs Group decreased their target price on shares of Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Monday, May 13th. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 target price on shares of Revance Therapeutics in a report on Friday. Finally, Piper Sandler decreased their target price on shares of Revance Therapeutics from $11.00 to $6.00 and set an “overweight” rating for the company in a report on Friday. Five analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Revance Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $11.89.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.